Scilex Holding (SCLXW) Net Margin (2022 - 2026)
Scilex Holding (SCLXW) recorded quarterly Net Margin of 503.14% in Q1 2026, up 26.46% quarter-over-quarter from 684.13% in Q4 2025, and up 1846.0% on a YoY basis from 25.86% in Q1 2025.
Scilex Holding (SCLXW) Net Margin (2022 - 2026) Analysis & Trends
Scilex Holding's Net Margin history runs 5 years deep, the most recent figure standing at 503.14% for Q1 2026.
- In Q1 2026, Net Margin rose 1846.0% year-over-year to 503.14%; the TTM figure through Mar 2026 stood at 1238.13% (down 107364.0% YoY), while the FY2025 annual figure was 1328.34%, down 118396.0% from the prior year.
- Net Margin was 503.14% for Q1 2026 at Scilex Holding, up from 684.13% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 188.99% in Q3 2022 to a low of 2435.93% in Q3 2025.
- Historically, Net Margin has averaged 438.51% across 5 years, with a median of 225.06% in 2022.
- The sharpest annual moves came in 2024 and 2025: Net Margin surged 84115 bps in 2024, then tumbled 240553 bps in 2025.
- A 5-year view of Net Margin shows it stood at 150.05% in 2022, then declined by 6 bps to 158.97% in 2023, then surged by 35 bps to 103.05% in 2024, then slumped by 564 bps to 684.13% in 2025, then gained by 26 bps to 503.14% in 2026.
- The last three Net Margin figures came in at 503.14% (Q1 2026), 684.13% (Q4 2025), and 2435.93% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 22.77% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 37.36% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.76% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 4.65% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -25.84% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 21.11% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 29.04% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -0.56% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 23.32% |
| 10 | Scilex Holding | - | - | 4.15 Mn | -503.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -503.14% |
| Dec 31, 2025 | -684.13% |
| Sep 30, 2025 | -2,435.93% |
| Jun 30, 2025 | -869.65% |
| Mar 31, 2025 | -521.60% |
| Dec 31, 2024 | -103.05% |
| Sep 30, 2024 | -30.40% |
| Jun 30, 2024 | -229.58% |
| Mar 31, 2024 | -223.97% |
| Dec 31, 2023 | -158.97% |
| Sep 30, 2023 | -871.54% |
| Jun 30, 2023 | -211.80% |
| Mar 31, 2023 | -290.62% |
| Dec 31, 2022 | -150.05% |
| Sep 30, 2022 | 188.99% |
| Jun 30, 2022 | -225.06% |
| Mar 31, 2022 | -134.22% |